Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

NCT04832438 is registered in ClinicalTrials.gov with Actuate Therapeutics Inc. as lead sponsor.

NCT NCT04832438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Lead sponsor
Actuate Therapeutics Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 18, 2030
Completion date
June 18, 2034
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, salivary gland cancer, salivary gland carcinoma, salivary gland neoplasms